Nominations are now open for the Superstars of STEM program, which supports and trains women in STEM to share their passion with the Australian community.
A total of 320 projects will receive $200 million in funding from the National Health and Medical Research Council (NHMRC) and the Medical Research Future Fund (MRFF) following a competitive process.
Bioethicist Dr Ainsley Newson talks mitochondrial donation, targeted testing and other ethical dilemmas ahead of the AACB AIMS 2018 Combined Scientific Meeting.
Dr Cathy Foley will start her new role at the end of September, and said her priority will be promoting science, STEM and women in science.
NSW BioCheers brings together members of the life sciences, therapeutics, medical technology, food and agriculture biotechnology sectors.
Biomedical research centre BioFab3D will be the home of a new play from immersive theatre company PlayReactive, based on the work of science-fiction pioneer Karel Čapek.
The funding will support ARC Future Fellowships, Australian Laureate Fellowships, Linkage Projects, and Industrial Transformation Research Hubs and Training Centres.
Number theorist Akshay Venkatesh has become the second Australian in history to win a Fields Medal, often described as the Nobel Prize for mathematics.
The AGTA conference, Australia's foremost genomic technology conference, is an essential event for researchers and industry representatives who work with genomic technologies.
The Royal Society has announced the winners of its 2018–19 medals and awards — 24 prizes that recognise exceptional researchers who make outstanding contributions to science.
The USA's targeting of so-called 'foreign free-riding' in trade deals could lead to a poor deal on pharmaceuticals for the UK post-Brexit.
Australian women at risk of having babies suffering severe mitochondrial disease may soon be able to have healthy children.
The prestigious NHMRC Research Excellence Awards recognise recent outstanding performance in the health and medical research field.
Gene therapies stand to benefit patients immensely, but there are questions about their commercial viability for pharmaceutical companies.
Although some malicious applications of synthetic biology may not seem plausible right now, they could become achievable with future advances.